Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Minute Insight: Pear Gets FDA’s STeP Designation For Chronic Pain Therapeutic

Executive Summary

Pear Therapeutics is developing the Pear-010 digital therapeutic for virtual reality-delivered pain reduction in adults with acute postoperative and postprocedural pain. Its inclusion in FDA’s Safer Technologies Program (STeP) program suggests the FDA is committed to continuing that program for products that treat non-life-threatening or reversible conditions.

You may also be interested in...



Minute Insight: OxfordVR’s Virtual Reality Program Treats Agoraphobia In Trial

Results of a 346-patient randomized trial run by the UK’s National Health Service showed the automated virtual reality system developed by researchers at Oxford University helped people with agoraphobia re-engage with day-to-day activities outside their home.

Minute Insight: Pear Therapeutics Inks Agreement With SoftBank To Develop Japan-Focused Digital Therapeutic

Pear Therapeutics signed an agreement with SoftBank to develop a Japan-focused digital therapeutic, but regulatory questions remain.

Pear Adds Spanish Version Of Its Addiction Therapy PDTs

Availability of Spanish-language prescription digital therapeutics for the treatment of substance use disorder and opioid use disorder will address important health equity and health care disparities, according to Pear.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

MT145305

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel